Illustration of Altered Glucose Dependency in Drug-Resistant Cancer Cells
Glucose uptake and its catabolism take place through glycolysis. (A) The glycolysis pathway is linked with the tri-carboxylic acid pathway (TCA) for a full breakdown of glucose molecules. The cancer cells upregulate glycolytic enzymes, thus increasing pyruvate and lactate production. Pyruvate acts as an antioxidant, while lactate makes the cellular medium acidic, which helps in cancer growth. HIF-1a, MYC, KRAS, and several other oncogenic proteins are involved in accelerating the transcription of the much-needed glycolytic genes. The glycolysis in cancer cells differs from that in normal cells. In cancer cells, the breakdown of glucose is incomplete, and a large amount of lactate is generated (acronyms: GLUT1: glucose transporter 1, HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PKM2: pyruvate kinase M2, LDHA: lactate dehydrogenase A, MTC: monocarboxylate transporters, TCA cycle: tricarboxylic acid cycle, HIF-1α: hypoxia inducible factor 1-alpha, red ↑ indicates upregulation). (This figure was drawn using the Bio Render app). (B) The aerobic glycolysis/Warburg pathway is connected with several metabolic processes that sustain the cancer cells’ ability to survive in difficult environments. Other than the catabolic pathway, glycolysis is associated with cancer biomass synthesis and antioxidative mechanisms. The flow describes the association of glycolysis with various mechanisms.